NEW YORK, NY / ACCESSWIRE / November 14, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Viking Therapeutics, Inc. ("Viking" or the "Company") (NASDAQ:VKTX). Such investors are ...
Right now, Eli Lilly dominates the weight loss industry thanks to its dual agonists Mounjaro and Zepbound. Viking ...
Since then, Viking has reiterated this encouraging data from trials of the injectable candidate and reported favorable data ...
5don MSN
A new stronger Ozempic is coming. Here’s what to knowNovo Nordisk (NVO) teased some new details about a potential Ozempic ...
H.C. Wainwright has recently reiterated Viking Therapeutics Inc (VKTX) stock to Buy rating, as announced on November 4, 2024, according to Finviz. Earlier, on September 11, 2024, JP Morgan had ...
Viking Therapeutics has more than one highly promising clinical-stage candidate. It doesn't face much in the way of financial barriers to implementing its strategy. It's also a very appealing partner ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback